Copyright Rib-X, Inc – All Rights Reserved Susan Froshauer, Ph.D. President and CEO

Copyright Rib-X, Inc – All Rights Reserved Our Mission To Rapidly Design and Develop the Next Generation of Antibiotics Active Against Drug Resistant Bacteria

Many Antibiotics Inhibit the Ribosome 50S30S Zithromax Biaxin Zyvox Ketek Cleocin Chloromycetin Synercid Inhibitors Aminoglycosides Tetracyclines mRNA Decoding Peptide bond formation

Copyright Rib-X, Inc – All Rights Reserved Rib-X Business Plan Fully exploit Rib-X research and development capability to build a sustainable company Establish a strong pipeline of differentiable drugs Partnerships to leverage our assets and to expand outreach and global potential Revenue via such commercialization partnerships and ultimately a focused Rib-X sales force

Copyright Rib-X, Inc – All Rights Reserved Waves of Programs Build Pipeline Clinical Trials Phase 2 Clinical Trials Phase 1 Late Preclinical Clinical Trials Phase 2 Clinical Trials Phase 1 Commercial Partnership IND Copyright Rib-X Inc – All Rights Reserved NCE Development R  New Programs Commercial Partnership Drug Candidates R  03 Late Preclinical R  01 NCE Development Late Preclinical Clinical Trials Phase 1 Clinical Trials Phase 3

Copyright Rib-X, Inc – All Rights Reserved Business Highlights Research Initiated, June, ‘01 $ 9.5 MM, Series A, Dec., ‘01 $ 63.5 MM, Series B, May ’03 Multiple, Parallel & Distinct Drug Dev Programs Clinic with 1st Program during 2005 Commercial Partnerships in Phase I/II

Copyright Rib-X, Inc – All Rights Reserved Rib-X Culture 50 Employees 42 Ph.D.s, 1 MBA, 3 Specialized Training Local Institutions- Yale, Large Pharma US Biotech Companies and other Academic Institutions International

Copyright Rib-X, Inc – All Rights Reserved Rib-X Benefits from CT Rib-X Benefits from CT Nucleation and Cash Flow

Copyright Rib-X, Inc – All Rights Reserved Scientific Founders Thomas A. Steitz, Ph.D. SAB Chair and Co-founder Yale University Peter B. Moore, Ph.D. Co-founder Yale University Harry F. Noller, Ph.D. Co-founder University of California, Santa Cruz John N. Abelson, Ph.D. Co-founder California Institute of Technology William L. Jorgensen, Ph.D. Co-founder Yale University

Copyright Rib-X, Inc – All Rights Reserved Yale Technology Transfer Exclusive Licenses to: Ribosome Crystal Structure  Patent  Know-how Computational Chemistry Software & Code

Copyright Rib-X, Inc – All Rights Reserved Private Equity Investors, Including CT Venture Capital ABS Ventures Axiom Venture Partners Cardinal Partners Connecticut Innovations EuclidSR Partners Oxford Bioscience Partners S.R. One, Limited Warburg Pincus (Series B Lead) Zero Stage Capital

Copyright Rib-X, Inc – All Rights Reserved Connecticut Innovations Valuable to Rib-X Connecticut Innovations Private Equity Fund  Seed Investors($ 1.2 MM) Connecticut Innovation’s Lab Space  Science Park Incubator Space  Modest interest loan to build 29,000 square ft George Street Laboratory Facilities ($ 3.1 MM, 5yrs)

Copyright Rib-X, Inc – All Rights Reserved Connecticut Benefits- Increase Rib-X Runway R & D Tax Credit Preferential Personal Property Tax New Haven Enterprise Zone

Copyright Rib-X, Inc – All Rights Reserved Rib-X Outreach to Organizations Smoothes the Way Yale  SOM  Library  Fee for Service- Equipment, Keck Facility  Scientific Community  Educated Workforce CBIA  Bulk buying power (health insurance)  HR Resources/Information  Training and Key Certifications CURE  On-line info (permitting requirements)  Promotion of Biotech Cluster Build

Copyright Rib-X, Inc – All Rights Reserved CT Might Do More…. Patient Money and Incentives

Copyright Rib-X, Inc – All Rights Reserved Stimulating the Biotech Cluster $$ Seed FundingMezzanine Diversity of Business Plans- Synergies- Benefits Involve Local Pharma/Biotech- Define Needs Administrative Resources Connected, Committed, Savy Mentors Visionary Facilities- High Cost Equipment

Copyright Rib-X, Inc – All Rights Reserved Susan Froshauer, Ph.D. President & CEO (203) Thank you.